MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia (Q39174681)

9 September 2017

title

MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia (English)

1 reference

ubiquitin-proteasome system

9 September 2017

main subject

0 references

author name string

Liuping Zhang

1

1 reference

9 September 2017

Hua Tang

2

1 reference

9 September 2017

Yao Kou

3

1 reference

9 September 2017

Rui Li

4

1 reference

9 September 2017

Yueyong Zheng

5

1 reference

9 September 2017

Qiang Wang

6

1 reference

9 September 2017

Xiaoyu Zhou

7

1 reference

9 September 2017

Liangbin Jin

8

1 reference

9 September 2017

publication date

28 March 2013

1 reference

Journal of Cancer Research and Clinical Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

139

1 reference

9 September 2017

issue

7

1 reference

9 September 2017

page(s)

1105-1115

1 reference

Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Mechanism of increased lipolysis in cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The role of cytokines in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Identification of ubiquitin ligases required for skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

IKKbeta/NF-kappaB activation causes severe muscle wasting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Ubiquitin-protein ligases in muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Interleukin 6 as a key regulator of muscle mass during cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Cancer cachexia: developing multimodal therapy for a multidimensional problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Definition and classification of cancer cachexia: an international consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Signaling pathways perturbing muscle mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Nuclear factor-kappaB: its role in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Nuclear factor-kappa B signaling in skeletal muscle atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Synergism between arsenite and proteasome inhibitor MG132 over cell death in myeloid leukaemic cells U937 and the induction of low levels of intracellular superoxide anion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The therapeutic potential of pharmacological chaperones and proteosomal inhibitors, Celastrol and MG132 in the treatment of sialidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Waste management - cytokines, growth factors and cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Mechanisms of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00432-013-1412-6

Prevention of muscle disuse atrophy by MG132 proteasome inhibitor

21 January 2018

1 reference

12 December 2020

Glucose metabolism in cachectic patients with colorectal cancer.

1 reference

12 December 2020

MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFκB pathways

1 reference

12 December 2020

Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia

1 reference

12 December 2020

MG132, a proteasome inhibitor, induces apoptosis in tumor cells

1 reference

12 December 2020

Crossroads of cytokine signaling--the chase to stop muscle cachexia

1 reference

12 December 2020

Comparative study of the influence of proteasome inhibitor MG132 and ganciclovir on the cytomegalovirus-specific CD8( ) T-cell immune response

1 reference

12 December 2020

MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-κB/TGFβ1 pathway

1 reference

12 December 2020

Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice

1 reference

12 December 2020

Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury.

1 reference

12 December 2020

Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132.

1 reference

12 December 2020

10.1007/S00432-013-1412-6

Identifiers

DOI

1 reference

9 September 2017

1 reference